A Nature study from TIGEM maps a previously unknown TBK1–ULK1 signaling route that controls TFEB, the master regulator of lysosomal biogenesis and autophagy. The group identifies druggable points within the pathway, framing TFEB control as a therapeutic lever for lysosomal storage diseases and cancer. The key development is the mechanistic bridge from kinase signaling to TFEB regulation, giving the field a more actionable target landscape than TFEB biology alone. For translational biotech teams, the report provides a concrete rationale for pathway-targeted screening rather than relying on indirect TFEB activation through cellular stress endpoints.